Genetic control of specific immune suppression. I. Experimental conditions for the stimulation of suppressor cells by the copolymer L- glutamic acid50-L-tyrosine50 (GT) in nonresponder BALB/c mice by unknown
GENETIC CONTROL OF SPECIFIC IMMUNE SUPPRESSION
I. Experimental Conditions for the
Stimulation of Suppressor Cells by the Copolymer
L-Glutamic Acids°-L-Tyrosine s° (GT) in Nonresponder
BALB/c Mice*
BY PATRICE DEBRE,$ JUDITH A. KAPP, AND BARUJ BENACERRAF
(From the Deparment ofPathology, Harvard Medical School, Boston, Massachusetts 02115)
In earlier studies from our laboratory, mice that are nonresponders (H2P, H-
29, H-28) to the terpolymer of L-glutamic acids°-L-alanine3°-L-tyrosine'° (GAT)'
were shown to develop suppressor T cells capable of inhibiting GAT-specific
responses to GAT complexed with methylated bovine serum albumin (GAT-
MBSA) (1). This finding raised several important points: (a) Could suppressor T
cells be demonstrated in nonresponder mice immunized with antigens other
than GAT? (b) Do all nonresponder strains unable to form an antibody response
to an antigen under H-2-linked Ir gene control develop suppressor cells? (c) If
the ability to generate suppressor cells in response to an antigen is observed in
some mouse strains but not in others, are these phenotypic differences under
genetic control? (d) If such genetic control is observed, are the responsible genes
linked to the major histocompatibility complexof the mousein a manner similar
to what has been demonstrated for the control of antibody responses by H-2-
linked Ir genes (2, 3)?
We have selected the copolymer of L-glutamic acids° and L-tyrossnns° (GT) to
investigate these points for the following reasons. Firstly, it was reported that
GT failsto induce antibody responses in any of the inbred strains of mice tested,
although it is immunogenic in some individual random-bred Swiss mice (4), in
strain 13 guinea pigs (5), and in some inbred rat strains (6). Secondly, the
copolymer GT can be complexed readily with positively charged MBSA and, as
will be shown, GT-MBSA is immunogenic for mice unable to form antibody
responses to GT. Thirdly, we could use the same technique that was used
* This investigation was supported by U. S. Public Health Service Grant AI-09920 from the
National Institute of Allergy and Infectious Diseases.
f Recipient of a fellowship from the French Ministry of Foreign Affairs.
' Abbreviations used in this paper: CFA, complete Freund's adjuvant; DNP-KLH, 2,4-dinitro-
phenyl conjugate of keyhole limpet hemocyanin; GAT, random terpolymer of L-glutamic acids°-L-
alanine3°-L-tyrosine'°; GAT-MBSA, GAT complexed to methylated bovine serum albumin; GT,
random copolymer of L-glutamic acids°-L-tyrosine"; GT-MBSA, GT complexed to methylated
bovine serum albumin; GAT-SRBC, GAT coupled to sheep red blood cells; MBSA, methylated
bovine serum albumin; PFC, plaque-forming cells ; RAMG, polyvalent rabbit antimouse IgG;
SRBC, sheep red blood cells; TNP-SRBC, 2,4,6-trinitriphenyl conjugate of sheep red blood cells.
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successfully for the demonstration of GAT-specific T cells to investigate whether
preimmunization with GT stimulated specific immune suppression (1, 7) .
In this paperwe verify that GT does not induce a detectable antibody response
in a large number of inbred mouse strains and demonstrate that they can
nevertheless respond to GT-MBSA. We then establish that preimmunization
with GT inhibits primary and secondary responses to GT-MBSA in BALB/c
mice, andthat such unresponsiveness can be transferred to syngeneic recipients
with spleen cells or thymocytes from GT-primed BALB/c mice .
In a companion paper, we will show that the development of specific immune




All mice were purchased from Jackson Laboratory, Bar Harbor, Maine or the Health
Research Laboratories, Buffalo, New York, or were bred in our animal facilities . Mice used in
these studies were from 2 to 8-mo old andwere maintained on acidifiedchlorinated drinking water
and laboratory chow ad libitum .
Antigens .
￿
Two preparations of GT with an average mol wt of 30,500 and 31,800 daltons,
respectively,andonepreparation of GAT, mol wt 35,000, were purchased from Miles Laboratories
Inc., Miles Research Div., Elkhart, Ind . ThetwoGT preparations were identical in theirimmuno-
logical properties . 10 mg per ml stock solutions were prepared in normal saline containing 1%
Na 2C03 atpH 9.0 to 9.5 . MBSA wasprepared according to themethod ofSueoka andCheng (8) .
The GT-MBSA was prepared using the techniques described for thepreparation ofGAT-MBSA
complexes (9), i.e ., MBSA (5 mg per ml) was added dropwise, while stirring, to a 1 mg per ml
solution of GT . After a 20-min interval during which maximum floculation and aggregation
occurred, the precipitate ofGT-MBSA was washed three times with saline .
Immunization . Mice were immunized intraperitoneally with 10 Pg or 100 ug of GT . The
copolymer was administered in a 10% solution of magnesiumand aluminum hydroxides, Maalox
(William H. Rorer, Inc., Fort Washington, Pa .), or in a mixture of Maalox and pertussis vaccine
(Eli Lilly & Co ., Indianapolis, Ind.), or emulsified with an equal volume of complete Freund's
adjuvant containing 0.5 mg per ml of mycobacterium butyricum (CFA) (Difco Laboratories,




A modification of the Farr technique, as previously described (10),
was used to determine the antigen-binding capacity of the serum. Radioiodinated [125IIGT was
diluted with phosphate-buffered saline containing 1% normal mouseserum to aconcentration of 2
x 10-eM and a sp act between 0.2 and 4 Ci/g . Serum samples were diluted to 1:5 for assay .
Hemolytic Plaque Assay .
￿
The antibody response toGT andGT-MBSAwas studiedby enumer-
ating the number of plaque-forming cells (PFC) per spleen at various times after immunization
using a modification of the Jerne hemolyticplaque technique described by Pierce et al . (11) . IgM
PFC were enumerated after incubation of indicator red cells and spleen cells in agarose using
guinea pig serum as a source of complement . IgG PFC were developed with polyvalent rabbit
antimouse IgG (RAMG) and complement .
In preliminary experiments, it was observed that GT-coated sheep redblood cells (SRBC) could
not be used as indicator cells to detect GT-specific PFC as they nonspecifically agglutinated .
However, we observed that antibody responses to GT-MBSA could be assayed on SRBC coated
with the cross-reacting terpolymer GAT (GAT-SRBC) . Thetechnique for thepreparation of GAT-
SRBC and the reliability in the hemolytic plaque assay for this antigen have been described
elsewhere (12) . In preliminary experiments, thenumber ofGT-specific plaqueswasdetermined by
subtracting the number ofPFC inhibited by soluble GT from the number of plaques detected on
GAT-SRBC in theabsence ofinhibition . It was verified,however, that one coulduse either GAT or
GT as specific inhibitors of IgGPFC andobtain thesame results . Therefore, forconvenience and in
accord with the previous procedure described for the GAT system, 50 wg of soluble GAT has been
used to reproducibly inhibit all IgG-specific PFC induced by GT immunization . We have consid-
ered them operationally as GT-specific plaques.1438
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Results
Antibody Response to GT or GT-MBSA In Vivo . Mice were immunized
intraperitoneally with 100 Wg GT in CFA, and 21 days later were challenged
with the same dose of antigen . Individual sera obtained 7 days after secondary
immunization were analyzed in duplicate . Of 11 inbred and 8 congenic resistant
strains tested bearing 13 different H-2 haplotypes, none showed a significant
GT-specific antibody response, as detected by the binding of 1251-labeled GT
(Table I) . In contrast, 3 outof 15 random-bred Swissmice made detectable levels
of anti-GT antibodies . We also studied the antibody response in selected mouse
strains to GT, usingthehemolytic plaque assay, 7 days afterprimaryimmuniza-
tion with 100 p,g of GT in Maalox-pertussis or CFA. The results of these
experiments are presented in Table II . GT immunization with either Maalox-
pertussis or CFA did not stimulate a significant PFC response detectable on
GAT-coated SRBC in any of the four strains tested . Inasmuch as the plaques
were developed with both RAMG and guinea pig complement, the assay should
have detected both IgM and IgG plaques if they had been present in the spleens
of GT-immunized mice . The same mouse strains responded to immunization
with GT-MBSAinCFA with the productiononday 7 ofspecificIgGplaques . The
number ofPFC per spleen detected was comparable in all four strains and was
also of the same order ofmagnitude as the number ofPFC per spleen that these
mice usually produce after immunization with GAT-MBSA (12) .
No specific IgMPFC were seen at either 4 or 7 days after immunization with
GT-MBSA in CFA in A/J or BALB/c mice . Thus, the antibody response of mice
to GT-MBSA is restricted for as yet undetermined reasons to the IgGclasses, as
was also observed in the response to GAT or GAT-MBSA .
Effects of GT on the Immune Response to GT-MBSA .
￿
BALB/c mice were
injected intraperitoneally with 10gg or 100 jigofGT in Maalox or Maalox alone
3-7 days before immunization with GT-MBSA. All mice were sacrificed 7 days
later and theirspleensexamined for GT-specific IgGPFC (Table III) . Immuniza-
tion with either 10 or 100 Wg of GT 3, 5, or 7 days before GT-MBSA challenge
caused a significant decrease in the antibody response of BALB/c mice to GT-
MBSA . The tolerance induced by GT preimmunization was specific, since the
administration of 100 jig ofGT in Maalox failed to suppress the primary anti-
DNP PFC response to an unrelated antigen DNP-KLH, as detected by an
hemolytic plaque assay using TNP-conjugated SRBC as indicator cells (data not
shown) . To determine whether the inhibition of the primary response to GT-
MBSA by GT preimmunization observed on day 7 was an absence of response or
simply a delay in the antibody response, the PFC response to GT-MBSA of
BALB/c mice pretreated with 100 lag GT in Maalox or with Maalox alone was
assayed at various times up to 15 days after immunization . As shown in Fig . 1,
the primary IgGPFC response to GT-MBSA can be detected on day 4, peaks on
day 7, and decreases considerably by day 15 . During all this time, the animals
pretreated with GT failed to make a significant antibody response .
Transfer of GT-Specific Tolerance to Normal, Syngeneic Recipients .
￿
An
experiment was performed to determine whether the inhibition of the antibody
response to GT-MBSA in BALB/c mice caused by GT preimmunization was an
active process resulting from the stimulation of specific suppressor cells . TheP. DEBRi , J. KAPP, AND B. BENACERRAF
TABLE I
Immune Response to the GT Copolymer Measured by Antigen-Binding
Assay
Mean percentage of radiolabeled GT ligand-bound in Farr assay by a 1:5 dilution of
serum ± SE, from M. Dorf and B. Benacerraf (unpublished observations).
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ability ofBALB/c mice rendered tolerant to GT to transfer specific unresponsive-
ness to GT-MBSA to syngeneic recipients was investigated. BALB/c mice were
injected with either 100 Ag of GT in Maalox or Maalox alone. 3 days later, 20 x
108 spleen cells or thymocytes obtained from these two groups of animals were
transferred intravenously into normal syngeneic recipients, and all recipient
mice were immunized with GT-MBSA in CFA. Their antibody response was
assayed 7 days later. As can be seen in Table IV, the mice that received spleen
cells or thymocytes from mice preimmunized with GT showed decreased PFC
responses when compared to mice that received the same numbers of control
spleen cells or thymocytes. The conclusion can, therefore, be made that GT
induces suppressor cells in the spleen and thymus of BALB/c mice.
Kinetic Studies on the Stimulation and the Duration of Suppressor Ef-
fect. The data presented in Table III illustrate that specific suppression in
BALB/c mice can be stimulated by GT immunization as late as 7 days and as
early as 3 days before challenge with GT-MBSA. A more detailed study of the
kinetics of this phenomenon was performed. 100 ug GT in Maalox was injected
into six groups of BALB/c mice at times ranging from 28 days before to 1 day
after GT-MBSA immunization. The 7-day PFC responses are shown in Fig. 2.
The earliest that GT preimmunization causes a marked decrease in theresponse
to GT-MBSA is 3 days before immunization with GT-MBSA. At that time, the
suppressive effect is already maximal and is maintained unchanged, as deter-
Strain H-2 haplotype No. tested Antigen binding (± SE)
B10.A a 5 0.7 ± 1.4'
A/J a 4 1.9 ± 3.9
C57BL/10J b 4 -3.4 ± 2.4
B10.D2n d 5 6.4 ± 4.0
BALB/c d 3 -7.7 ± 3.7
B10.M f 5 -6.3 ± 4.0
HTG 9 4 3.4 ± 5.0
C3H.JK j 4 7.7 ± 4.3
C3H/HeJ k 4 12.3 ± 3.1
B10.BR k 5 -3.5 ± 3.2
BDP/J p 6 -1.2 ± 0.8
P/J p 3 2.1 ± 6.4
DBA/W q 8 8.6 ± 4.1
T138 q 3 -0.2 ± 2.5
SWR/J q 2 -6.1 ± 5.7
B10.RIII r 5 -9.7 -t 3.6
SJL/J s 5 -3.3 ± 1.7
B10.PL u 5 -12.0 ± 2.6
SM/J v 5 9.5 ± 4.1
Swiss random bred 3 44.8 ± 9.5
Swiss random bred 12 6.8 ± 1.61440
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TABLE II
Immune Response to GT and GT-MBSA Measured by PFCAssay
100 jig ofGT with Maalox andB . pertussis or CFA as adjuvant or 10 Wg of GT complexed with
MBSA with CFA was administered intraperitoneally . 7days later specific IgGPFC were detected
usingGAT-SRBC . Thenumber of IgG-specific PFC/spleen in A/JandDBA/1 mice immunizedwith
GT do not differ statistically from the number in unimmunized animals (556 ± 258 and312 ± 120,
respectively) .
TABLE III
Effect ofGT Immunization on the Primary Response to GT-MBSA in
BALBlc Mice in Vivo
10 Wg or 100 kg ofGT in alum was injected intraperitoneally 7, 5, or 3 days before
immunization with 10 lAg GT as GT-MBSA, using CFA as adjuvant . All mice were
sacrificed 7 days later .
mined by in vivo experiments, up to 21 days after GT priming . The intensity of
the suppression decreases by day 28 .
Effect of GT Priming on the Development of Secondary Responses to GT-
MBSA in BALBlc Mice . The effect ofGTprimingon the secondary response to
GT-MBSA was investigated using three types of immunization protocols . All
mice received two immunizations with GT-MBSA with an interval of 21 days .






A/J a GT M/p 4 687 ± 520
GT CFA 8 653 ± 257
GT-MBSA CFA 19 8,955 ± 1,239
A.BY b GT CFA 3 825 ± 825
GT-MBSA CFA 8 11,075 ± 2,124
BALB/c d GT M/p 4 381 ± 264
GT CFA 4 400 -t 234
GT-MBSA CFA 57 12,252 ± 729
DBA/1 q GT M/p 4 950 ± 592
GT CFA 4 <200
GT-MBSA CFA 16 7,374 ± 1,208
Day of injection
Dose of GT in
Maalox
IgG-specific PFC/spleen Inhibition
erg Mean ± SE %
None 12,294 - 2,129
Day - 7 10 1,302 - 576 90
Day - 5 100 1,000 ± 470 92
10 2,737 ± 1,325 78
Day - 3 100 950 ± 660 93
10 677 - 341 95P. DEBRE, J. KAPP, AND B. BENACERRAF
FIG. 1 .
￿
Effect ofGT preimmunization on the IgG PFC response of BALB/c mice to GT-
MBSA assayed at varioustimes after primary immunization . Mice were injected with 100
p,gGT in Maalox or only Maalox 3 days before immunization with 10 Wg GT asGT-MBSAin
CFA . Thegraphshowsthe arithmetic mean ofthe PFC response of four mice per group .
TABLE IV
Transfer of GT-Specific Suppression to Normal Syngeneic Recipients
(BALBlc Mice)
* 20 x 106 cells from donors immunized 3 days before with Maalox or 100,ug of
GT in Maalox were injected i.v . into normal syngeneic recipients . On the
same day, these animals were intraperitoneally immunized with 10 wg GT
complexed with MBSA in CFA. 7 days later, the number of Gt-induced IgG
PFC per spleen was enumerated using GAT-SRBC .
$ P < 0.03 .
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GT or Maalox was administered 3 days before GT-MBSA. In some animals GT
was injected once before secondary immunization ; in other animals once before
primary immunization ; and in a third group GT was administered before both
primary and secondary immunization . No significantsuppression of the second-
Cells transferred* Specific IgG PFC/spleen Inhibition$
Mean ± SE %
Control spleen 19,468 ± 3,184 87 GT-primed spleen 2,687 ± 1,032
Control thymus 22,781 ± 6,861 85 GT-primed thymus 3,587 ± 1,4061442
￿
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FIG. 2.
￿
Effect of the time interval between GT and GT-MBSA immunization on the
suppression by GT of the IgG PFC response to GT-MBSA in BALB/c mice . Response was
assayed 7 days after challenge with GT-MBSA inCFA . Data are presented as percentage of
control response of animals preimmunized with Maalox alone, 7 days before GT-MBSA
challenge .
ary response to GT-MBSA was observed when GT was injected before primary
immunization (Table V) . However, when GT was injected 3 days before second-
ary challenge with GT-MBSA, the specific IgG PFC response is clearly de-
creased onday 4 but noton day 7 . IfGT is administered twice, a first time 3 days
before GT-MBSA priming and again 3 days before the secondary challenge, the
secondary response to GT-MBSA is significantly decreased as compared to the
control response both on days 4 and 7 after GT-MBSA challenge .
Discussion
The random copolymer of L-glutamic acid and L-tyrosine, which is immuno-
genic in strain 13 guinea pigs (5) and in rats bearing theH-1 a orH-1c haplotype
(6), stimulates antibody responses by some random-bred Swiss mice, but notby
the 19 inbred strains investigated. Nor can GT elicit primary PFC responses in
four selected inbred mouse strains bearing different H-2 haplotypes . It would
appear, therefore, that in mice Ir genes controlling antibody responses to GT are
not widely represented . Nonresponder mice can, however, produce anti-GT
antibodies after immunization with GT complexed with an immunogenic car-
rier, MBSA, as observed in other systems (9, 13) . The restricted immunogenicity
ofGT for mice renders this antigen well suited for studies on the stimulation of
specific immune suppression using the types of protocols which permitted the
identification of GAT-specific suppressor T cells in mice bearing the H-2- a .
8
haplotypes and unable to respond to GAT (1) .
The experiments reported in this paper were designed to establish the condi-
tions for demonstration of the suppressive properties of GT in a suitable mouse
strain as a model, with the view to apply these techniques to the study of the
genetic factors controlling the stimulation of specific immune suppression . The
data document the tolerogenic properties of microgram amounts of GT on the
specific response of BALB/c mice immunized with GT-MBSA in CFA . GT-
specific tolerance could be transferred to normal, syngeneic recipients by spleenP . DEBRA, J . KAPP, AND B . BENACERRAF
TABLE V




























' 100Ag ofGT in Maalox wasadministered intraperitoneally 3days before aprimary
immunization or a secondary immunization with 10 Ag ofGT as GT-MBSA in CFA.
4 days and 7 days after thesecondary immunization with GT-MBSA, thenumber of
IgG-specific PFC per spleen were enumerated using GAT-coated SRBC . P values
between each group and the control group are shown in parentheses. BALE/c
control animals, which received aprimary injection ofGT-MBSA on the same day
as the above secondary immunization, develop 2,675 ± 1,760 IgG-specific PFC at
day 4 and 6,881 :t 1,321 at day 7 .
f Mean ± SE .
§ Day relative to second injection ofGT-MBSA .
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cells or thymocytes ofGT-primed animals, demonstrating a role for suppressor
cells in this phenomenon .
Before considering the properties of GT-specific immunosuppression in
BALB/c mice, it is appropriate to discuss some of the experimental conditions
which had to be used in this study and their implications . (a) Specific immune
suppression is best shown on primary PFC responses when synthetic polypep-
tide antigens such as GAT or GT are used . (b) To assay GT-specific PFC
responses, we used SRBC coated with GAT rather than with GT because GT-
coated SRBC were notstable in the assay . The antibody responses to GT-MBSA
detected were, therefore, those which are cross-reactive with GAT. This is no
indication, however, that a large number of GT-specific plaques have been
missed by the assay using GAT-SRBC . This statement is based on the large
number of IgG PFC per spleen detected by this technique after immunization
with GT-MBSA, anumberwhichdoes not differ significantly from that observed
using the same assay after immunization with GAT-MBSA (12) . Furthermore,
the conclusions concerning the stimulation of GT-induced specific suppression
are not affected by the fact that antibody-forming cells elicited by GT-MBSA
have been detected on GAT-SRBC . We have, therefore, considered the PFC
detected with GAT-SRBC in mice immunized with GT-MBSA as GT-specific
plaques operationally. (c) For reasons still undetermined, these linear copoly-
mers and complexes ofthese copolymers with MBSA do notstimulate detectable
IgM PFC in vivo or in vitro and elicit only IgGPFC responses (12) .
The following conclusions were reached in our study of GT-specific suppres-
§Day - 24 Day -3 Day +4 Day +7
leg lig
None None 21,095 ± 3,115 22,125 ± 2,594
None 100 2,185 ± 1,156 17,862 ± 3,1821444
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sion ofthe response to GT-MBSA ofBALB/c mice. The stimulationofsuppressor
cells was observed with another synthetic polypeptide besides GAT in nonre-
sponder mice . The suppression elicited by GT preimmunization ofBALB/c mice
resembles operationally the specific suppression stimulated by GAT in DBA/1
mice with respect to the degree oftolerance achieved, the dose range of antigen
required, the time of appearance, and the length of time when suppression is
effective in vivo after immunization (1, 7, 14).
The experiments on the effect of GT on the secondary response to GT-MBSA
illustrate several interesting points. (a) Specific suppression of secondary re-
sponsesis muchmore difficultto achievethan suppression ofprimary responses.
100 pg of GT administered 3 days before a primary challenge with GT-MBSA
suppress effectively the primary antibody response, but was only able, when
administered before a secondarychallenge, to cause ashortdelayin the develop-
ment of PFC response on day 4 and did not affect the level of the response
observed on day7. (b) IfGT is administered 3 days before primaryimmunization
with GT-MBSA, which effectively suppresses the primary antibody response, a
characteristic secondary response is elicited by GT-MBSA challenge, indicating
that GT immunization did notsuppress primingfor thesecondary response. The
activity ofsuppressorcells is, therefore, limited in time andcan be overcome by
repeated immunizations. (c) The most effective suppression of the secondary
GT-MBSA response detectable on days 4 and 7 after secondary challenge re-
quired the administration ofGT before both theprimaryandsecondary injection
with GT-MBSA. However, in these experiments with GT and in other experi-
ments with GAT, no evidence was obtained that a high level of memory was
achieved inthe specific suppressor cell population by repeated injection (14).
Thestudy ofspecific suppressorcellsandoftheir specific active productsis one
of the most fascinating and potentially useful areas of cellular immunology.
Much remains to be learned concerning these phenomena. The use of the
copolymers of L-amino acids such as GT and GAT to stimulate the formationof
specific suppressor cells in nonresponder strains may prove to be the most
effective and reliable technique to investigate specific immune suppression.
These products, incontrast to conventional antigens, stimulate suppressor cells
when administered in microgram amounts, even in the presence ofadjuvants,
withoutthedevelopment ofspecific antibody whichmay complicatethe interpre-
tation ofthe results.
Summary
In the present studies we have confirmed thatthe random copolymerOfL-glu-
tamic acid"-L-tyrosine" (GT) fails to induce an antibody response in a large
number of inbred strains of mice. Nevertheless, GT complexed to methylated
bovine serum albumin (MBSA) elicits a GT-specific IgG PFC response in vivo.
Furthermore, injection of BALB/c mice with 10 to 100 jig of GT specifically
decreases their ability to develop anti-GT PFC responses to a subsequent
challenge with GT-MBSA. GT-specific tolerance can be transferred to normal,
syngeneic recipients by spleen cells or thymocytes ofGT-primed animals. These
results indicate that the stimulation of suppressor cells can be observed innonresponder mice with another synthetic polypeptide besides GAT . Various
parameters of GT-specific immunosuppression in BALB/c mice are described.
The application ofthese techniques to the study ofthe genetic factors controlling
the stimulation of specific immune suppression is discussed.
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